There is good news for
Thermo Fisher Scientific
's (
TMO
) shareholders as the Board has approved the initiation of a
quarterly cash dividend. This move is based on the company's
adopted strategy of effective capital deployment that strives to
create shareholder value. This proves the company's
confidence to return value to investors through dividend payments
besides pursuing opportunities that generate long-term growth.
The Waltham, Massachusetts based company will pay the initial
quarterly dividend of 13 cents a share on April 16, 2012, to
shareholders of record as on March 15, 2012. On an annualized
basis, this equates to a payout of 52 cents, translating into a
dividend yield of roughly 0.9% based on the closing price on
February 29.
Thermo Fisher posted better-than-expected fourth-quarter fiscal
2011 results amidst a challenging backdrop in the government and
academic end markets. The company's revenues and earnings were
ahead of the Zacks Consensus Estimates, backed by strong growth for
instruments serving industrial and applied markets and at the
Clinical Diagnostics business besides strong margin trends and
sturdy performance in the emerging markets.
Effective capital deployment has been one of the key
contributors toward EPS growth. Thermo Fisher repurchased 7 million
shares for $350 million during the most recent quarter (24.5
million shares for $1.3 billion during 2011) and was left with $650
million of authorization through November 2012. As a result of this
continuous buyback program the outstanding share count at the end
of the quarter stood at $376 million, down 5.7% from the year-ago
period, thus boosting the bottom line. Based on a strong cash
balance, the company has been strengthening its portfolio banking
on suitable acquisitions, the largest being Dionex and Phadia.
However, the company is up against increasing headwinds in the
government and academic markets. The situation in Europe might put
academic budgets under the scanner in most European nations.
Players in this niche like
Life Technologies
(
LIFE
) and
Illumina
(
ILMN
) among others are facing a similar crisis. The company, however,
believes that the end markets would be consistent with 2011 levels.
We expect growth to moderate if the economic situation
worsens.
We have a Neutral recommendation on Thermo Fisher. The stock
retains a Zacks #3 Rank (Hold) in the short term.
ILLUMINA INC (
ILMN
): Free Stock Analysis Report
LIFE TECHNOLOGS (
LIFE
): Free Stock Analysis Report
THERMO FISHER (
TMO
): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment
Research